---
title: Nalbuphine
description: >-
  Nalbuphine is prescribed for the relief of moderate to severe pain. It is also
  used preoperatively, as a supplement to balanced anesthesia, and for
  obstetrical analgesia during labor.  It's a synthetic opioid analgesic. It
  acts as a κ-opioid receptor agonist and a partial μ-opioid receptor antago...
is_banned: false
lastModified: '2025-09-22T17:21:53.676Z'
faqs:
  - q: >-
      What is the recommended dosage for Nalbuphine?**


      **A:** Adults: 10mg IV/IM/SC every 3-6 hours, maximum 20mg single dose,
      and 160 mg/day. Children (>1 year): 0.1-0.2 mg/kg IV/IM/SC every 3-4
      hours, not to exceed 20 mg per dose or 160 mg/day.
    a: >-
      A:** Adults: 10mg IV/IM/SC every 3-6 hours, maximum 20mg single dose, and
      160 mg/day. Children (>1 year): 0.1-0.2 mg/kg IV/IM/SC every 3-4 hours,
      not to exceed 20 mg per dose or 160 mg/day.
  - q: >-
      How does nalbuphine compare to morphine in terms of analgesic efficacy?**


      **A:** 10 mg of nalbuphine is considered to have comparable analgesic
      potency to 10 mg of morphine.
    a: >-
      A:** 10 mg of nalbuphine is considered to have comparable analgesic
      potency to 10 mg of morphine.
  - q: >-
      Can nalbuphine be used in patients with renal or hepatic impairment?**


      **A:**  Yes, but with caution. Dose reduction may be necessary due to
      potential for decreased drug clearance.
    a: >-
      A:**  Yes, but with caution. Dose reduction may be necessary due to
      potential for decreased drug clearance.
  - q: |-
      What are the signs of nalbuphine overdose?**

      **A:**  Respiratory depression, pinpoint pupils, sedation, and coma.
    a: 'A:**  Respiratory depression, pinpoint pupils, sedation, and coma.'
  - q: >-
      How is nalbuphine overdose treated?**


      **A:** Supportive care and administration of naloxone, an opioid
      antagonist, to reverse respiratory depression.
    a: >-
      A:** Supportive care and administration of naloxone, an opioid antagonist,
      to reverse respiratory depression.
  - q: >-
      Can nalbuphine be used during labor and delivery?**


      **A:**  It can be used, but with caution.  It can prolong labor and cause
      fetal bradycardia. Monitor newborns closely for respiratory depression.
    a: >-
      A:**  It can be used, but with caution.  It can prolong labor and cause
      fetal bradycardia. Monitor newborns closely for respiratory depression.
  - q: >-
      Does nalbuphine interact with other medications?**


      **A:** Yes. It interacts with CNS depressants (e.g., benzodiazepines,
      alcohol), enhancing their effects. Also interacts with drugs metabolized
      by the liver (CYP450 system).
    a: >-
      A:** Yes. It interacts with CNS depressants (e.g., benzodiazepines,
      alcohol), enhancing their effects. Also interacts with drugs metabolized
      by the liver (CYP450 system).
  - q: >-
      What are the withdrawal symptoms of nalbuphine?**


      **A:** Similar to other opioids: abdominal cramps, nausea, vomiting,
      restlessness, anxiety, sweating, and muscle aches.
    a: >-
      A:** Similar to other opioids: abdominal cramps, nausea, vomiting,
      restlessness, anxiety, sweating, and muscle aches.
  - q: >-
      Is nalbuphine addictive?**


      **A:** Yes, nalbuphine has the potential for addiction and dependence like
      other opioid medications.
    a: >-
      A:** Yes, nalbuphine has the potential for addiction and dependence like
      other opioid medications.
  - q: >-
      What is the mechanism of action of nalbuphine?**


      **A:** It acts as a kappa-opioid receptor agonist and a partial mu-opioid
      receptor antagonist in the central nervous system. This results in pain
      relief with fewer adverse respiratory effects than full mu-agonists,
      although respiratory depression can still occur.
    a: >-
      A:** It acts as a kappa-opioid receptor agonist and a partial mu-opioid
      receptor antagonist in the central nervous system. This results in pain
      relief with fewer adverse respiratory effects than full mu-agonists,
      although respiratory depression can still occur.
---
## **Usage**

Nalbuphine is prescribed for the relief of moderate to severe pain. It is also used preoperatively, as a supplement to balanced anesthesia, and for obstetrical analgesia during labor.  It's a synthetic opioid analgesic. It acts as a κ-opioid receptor agonist and a partial μ-opioid receptor antagonist.

## **Alternate Names**

Nalbuphine hydrochloride is the generic name. Brand names include Nubain and others which may vary regionally.

## **How It Works**

**Pharmacodynamics:** Nalbuphine primarily acts as an agonist at kappa-opioid receptors and as a partial antagonist at mu-opioid receptors in the central nervous system. This mixed action gives it analgesic effects while potentially causing less respiratory depression, pruritus, and nausea compared to pure mu-opioid agonists like morphine.

**Pharmacokinetics:**
* **Absorption:** Rapid onset of action (2-3 minutes intravenously, <10 minutes subcutaneously or intramuscularly).
* **Metabolism:** Primarily metabolized in the liver via conjugation with glucuronic acid.
* **Elimination:** Excreted primarily in the urine, with small amounts in bile and breast milk. The elimination half-life is approximately 5 hours.

**Mechanism of Action:** Binding to kappa-opioid receptors leads to analgesia. The partial mu-receptor antagonism may limit some of the typical opioid side effects but can also precipitate withdrawal symptoms in opioid-dependent individuals.

## **Dosage**

### **Standard Dosage**

#### **Adults:**

* **Pain Management:** 10 mg every 3-6 hours intravenously (IV), intramuscularly (IM), or subcutaneously (SC).  Maximum single dose: 20 mg. Maximum daily dose: 160 mg.
* **Anesthesia Supplement:**  Induction: 0.3 to 3 mg/kg IV over 10 to 15 minutes.  Maintenance: 0.25 to 0.5 mg/kg IV as needed.

#### **Children:**

* **> 1 year:** 0.1-0.2 mg/kg IV, IM, or SC every 3-4 hours. Maximum single dose: 20 mg. Maximum daily dose: 160 mg.
* **< 1 year:** Safety and efficacy not established.

#### **Special Cases:**

* **Elderly Patients:** Initiate at lower doses and monitor closely.
* **Patients with Renal Impairment:** Dose reduction may be necessary.
* **Patients with Hepatic Dysfunction:** Dose reduction may be necessary.
* **Patients with Comorbid Conditions:** Exercise caution in cardiovascular disease, respiratory impairment, or history of substance abuse.

### **Clinical Use Cases:**

* **Intubation:** Use as an analgesic adjunct during intubation procedures.
* **Surgical Procedures:**  Pre- and postoperative analgesia, supplement to balanced anesthesia.
* **Mechanical Ventilation:** May be used for pain control in ventilated patients.
* **Intensive Care Unit (ICU) Use:** Pain management in critically ill patients.
* **Emergency Situations:** May be used for pain control in acute settings, though other agents may be preferred.


### **Dosage Adjustments**

Adjust dosage based on patient's response, pain severity, organ function (renal/hepatic), and concomitant medications.


## **Side Effects**

### **Common Side Effects:**

* Drowsiness, sedation, dizziness, lightheadedness
* Nausea, vomiting, dry mouth
* Sweating, clammy skin, headache

### **Rare but Serious Side Effects:**

* Respiratory depression, apnea, bradycardia, hallucinations
* Allergic reactions (e.g., hives, difficulty breathing, swelling)

### **Long-Term Effects:**

Potential for tolerance, dependence, and withdrawal symptoms with prolonged use.


### **Adverse Drug Reactions (ADR):**

* Severe allergic reactions, respiratory depression, seizures, and severe bradycardia require immediate intervention.



## **Contraindications**

* Significant respiratory depression
* Acute or severe bronchial asthma
* Known or suspected gastrointestinal obstruction
* Hypersensitivity to nalbuphine


## **Drug Interactions**

Nalbuphine interacts with numerous medications, including:

* **CNS depressants:** Enhanced sedation and respiratory depression.
* **Alvimopan**: Increased risk of opioid withdrawal.
* **CYP450 inhibitors/inducers:** May alter nalbuphine metabolism.

Monitor closely when co-administering with other medications. Check for potential interactions before prescribing.


## **Pregnancy and Breastfeeding**

* **Pregnancy:**  Insufficient data to determine risk. Use only if clearly needed and benefits outweigh risks. Neonatal withdrawal syndrome is possible with prolonged use.
* **Breastfeeding:** Small amounts excreted in breast milk. Monitor infants for sedation and respiratory depression.


## **Drug Profile Summary**

* **Mechanism of Action:** κ-opioid receptor agonist, partial μ-opioid receptor antagonist.
* **Side Effects:** Drowsiness, dizziness, nausea, vomiting, respiratory depression.
* **Contraindications:** Respiratory depression, asthma, GI obstruction.
* **Drug Interactions:** CNS depressants, alvimopan, CYP450 modulators.
* **Pregnancy & Breastfeeding:** Use with caution.
* **Dosage:** Adults: 10 mg q3-6h (max 160mg/day). Children (>1yr): 0.1-0.2 mg/kg q3-4h.
* **Monitoring Parameters:** Respiratory rate, heart rate, blood pressure, mental status.

## **Popular Combinations**

Limited information suggests the combination of nalbuphine with other analgesics or anesthetics for synergistic effects. However, such combinations should be used with extreme caution due to the potential for increased adverse events. Combinations must be tailored to individual patient needs and monitored meticulously.


## **Precautions**

* **General Precautions:** Screen patients for respiratory issues, substance abuse, allergies, and organ dysfunction before administering.
* **Specific Populations:** Exercise caution in pregnant/breastfeeding women, children, elderly patients, and patients with comorbid conditions.
* **Lifestyle Considerations:** Avoid alcohol and other CNS depressants. Caution patients about driving and operating machinery.


## **FAQs (Frequently Asked Questions)**

### **Q1: What is the recommended dosage for Nalbuphine?**

**A:** Adults: 10mg IV/IM/SC every 3-6 hours, maximum 20mg single dose, and 160 mg/day. Children (>1 year): 0.1-0.2 mg/kg IV/IM/SC every 3-4 hours, not to exceed 20 mg per dose or 160 mg/day.


### **Q2: How does nalbuphine compare to morphine in terms of analgesic efficacy?**

**A:** 10 mg of nalbuphine is considered to have comparable analgesic potency to 10 mg of morphine.


### **Q3: Can nalbuphine be used in patients with renal or hepatic impairment?**

**A:**  Yes, but with caution. Dose reduction may be necessary due to potential for decreased drug clearance.


### **Q4: What are the signs of nalbuphine overdose?**

**A:**  Respiratory depression, pinpoint pupils, sedation, and coma.


### **Q5: How is nalbuphine overdose treated?**

**A:** Supportive care and administration of naloxone, an opioid antagonist, to reverse respiratory depression.


### **Q6: Can nalbuphine be used during labor and delivery?**

**A:**  It can be used, but with caution.  It can prolong labor and cause fetal bradycardia. Monitor newborns closely for respiratory depression.


### **Q7: Does nalbuphine interact with other medications?**

**A:** Yes. It interacts with CNS depressants (e.g., benzodiazepines, alcohol), enhancing their effects. Also interacts with drugs metabolized by the liver (CYP450 system).


### **Q8:  What are the withdrawal symptoms of nalbuphine?**

**A:** Similar to other opioids: abdominal cramps, nausea, vomiting, restlessness, anxiety, sweating, and muscle aches.


### **Q9: Is nalbuphine addictive?**

**A:** Yes, nalbuphine has the potential for addiction and dependence like other opioid medications.


### **Q10: What is the mechanism of action of nalbuphine?**

**A:** It acts as a kappa-opioid receptor agonist and a partial mu-opioid receptor antagonist in the central nervous system. This results in pain relief with fewer adverse respiratory effects than full mu-agonists, although respiratory depression can still occur.
